Want to see AU:S66 full AI Analyst Report?
S66 Stock Chart & Stats
AU$0.12
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.12
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.28
Previous CloseN/A
Volume4.30K
Average Volume (3M)6.77K
Market Cap
AU$18.90M
Enterprise ValueAU$4.42
Total Cash (Recent Filing)AU$18.01M
Total Debt (Recent Filing)AU$4.19M
Price to Earnings (P/E)48.3
Beta-0.71
Next Earnings
Feb 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.64%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding135,002,980
10 Day Avg. Volume4,300
30 Day Avg. Volume6,768
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)0.47
Price to Sales (P/S)0.77
P/FCF Ratio22.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and substantial equity provide financial resilience through uneven earnings periods. This reduces balance-sheet stress, preserves flexibility to fund operations, and gives the company a stronger buffer than a highly debt-funded peer during weaker trading conditions.
Improving Cash GenerationThe shift to positive operating and free cash flow improves the company’s ability to support operations internally. Although conversion weakened in 2026, sustained positive cash generation is a meaningful foundation for liquidity and long-term financial resilience.
Recovery From Earlier LossesProgress from earlier loss-making years indicates that the business has demonstrated some capacity to restore profitability over time. This recovery history provides evidence of an underlying operating base, even though recent results show that earnings quality remains inconsistent.
Bears Say
Sharp Revenue ContractionA substantial revenue decline weakens operating leverage and makes future margin recovery more difficult. If the contraction reflects persistent demand or distribution problems rather than a temporary fluctuation, it could reduce the scale and competitiveness of the business over coming periods.
Material Margin DeteriorationOperating losses and sharply lower net margins signal that the company is not consistently converting sales into earnings. Persistent margin pressure would limit cash accumulation, reduce reinvestment capacity, and make profitability more sensitive to changes in costs or product mix.
Weak Earnings QualityThe weak 2026 return on equity shows that the sizable equity base is not being converted into sustainable shareholder returns. Combined with weaker cash conversion, this raises concern that working-capital movements or cash costs may continue to constrain the quality of reported earnings.
Star Combo Pharma Ltd. News
S66 FAQ
What was Star Combo Pharma Ltd.’s price range in the past 12 months?
Star Combo Pharma Ltd. lowest share price was AU$0.10 and its highest was AU$0.28 in the past 12 months.
What is Star Combo Pharma Ltd.’s market cap?
Star Combo Pharma Ltd.’s market cap is AU$18.90M.
When is Star Combo Pharma Ltd.’s upcoming earnings report date?
Star Combo Pharma Ltd.’s upcoming earnings report date is Feb 23, 2027 which is in 179 days.
How were Star Combo Pharma Ltd.’s earnings last quarter?
Star Combo Pharma Ltd. released its earnings results on Aug 25, 2026. The company reported AU$0 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Star Combo Pharma Ltd. overvalued?
According to Wall Street analysts Star Combo Pharma Ltd.’s price is currently Overvalued.
Does Star Combo Pharma Ltd. pay dividends?
Star Combo Pharma Ltd. pays a Notavailable dividend of AU$0.003 which represents an annual dividend yield of 2.64%. See more information on Star Combo Pharma Ltd. dividends here
What is Star Combo Pharma Ltd.’s EPS estimate?
Star Combo Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Star Combo Pharma Ltd. have?
Star Combo Pharma Ltd. has 135,002,980 shares outstanding.
What happened to Star Combo Pharma Ltd.’s price movement after its last earnings report?
Star Combo Pharma Ltd. reported an EPS of AU$0 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.692%.
Which hedge fund is a major shareholder of Star Combo Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:S66
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Star Combo Pharma Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.20%
12-Months-Change
Fundamentals
Return on Equity
2.64%
Trailing 12-Months
Asset Growth
3.42%
Trailing 12-Months
Company Description
Star Combo Pharma Ltd.
Star Combo Pharma Limited is involved in the production and supply of health foods and dietary supplements across Australia and China. The company's activities are organized into two primary divisions: Star Combo and Austoyou Retail. It manages the full spectrum of natural health supplements and skincare products, encompassing their development, manufacturing, promotion, and sale. Distribution channels include a dedicated e-commerce platform for health-conscious consumers in China, alongside two brick-and-mortar retail stores situated in Sydney. Founded in 2004, Star Combo Pharma Limited's main office is located in Smithfield, Australia.
Technical Analysis
EVE Health Group Limited
―
Nuchev Pty Ltd
―
Holista Colltech Limited
―
Nutritional Growth Solutions Ltd.
―
Hydration Pharmaceuticals Co. Ltd.
―